Bifidobacterium breve M-16V: Ideal Probiotic for Infant Health

Bifidobacterium breve M-16V (M-16V) has become one of the best studied clinically effective probiotic strains that exert positive effects, particularly in infants, to support healthy growth and promote well-being. M-16V supplementation is specifically beneficial at reducing the risk of allergic disorders in infants as well as protecting the vulnerable preterm infants against premature birth complications such as necrotizing enterocolitis (NEC) and sepsis. M-16V has been demonstrated to promote early gut microbial colonization, which supports healthy growth and helps establish a healthy gastrointestinal and immune system. It also plays a role in regulating immune balance and inflammatory response to protect high-risk infants from NEC and allergy. The administration of M-16V to low or extremely low birthweight infants is effective at promoting the establishment of bifidobacteria-predominant gut microbiota and protecting newborns from the risks of necrotizing enterocolitis (NEC) and sepsis. Since 1994, M-16V has been used in over 150 neonatal intensive care units (NICU) in affiliated hospitals in Japan, Australia, New Zealand, and Singapore to support healthy growth for low-birth-weight infants.